Trial site
New York Presbyterian Hospital-Columbia University Medical Center
- 10running trials
- 8closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Conditions
- Head and neck cancer3 trials
- Aortic stenosis2 trials
- Bladder cancer2 trials
- Cervical cancer2 trials
- Colorectal cancer2 trials
- Heart failure2 trials
- Lung cancer2 trials
- Parkinson disease2 trials
- Acute myeloid leukaemia1 trial
- Barrett's oesophagus1 trial
- Coronary artery disease1 trial
- Diffuse large B-cell lymphoma1 trial
- and 9 more
- Phase
- Phase 1/25 trials
- Phase 12 trials
- Phase 22 trials
- Phase 31 trial
- Phase 41 trial
- Status
- Completed6 trials
- Active, not recruiting5 trials
- Recruiting5 trials
- Terminated1 trial
- Withdrawn1 trial
- Lead sponsor
- 4C Medical Technologies, Inc.1 trial
- 4D Molecular Therapeutics1 trial
- Acrivon Therapeutics1 trial
- Arcus Biosciences, Inc.1 trial
- Capsida Biotherapeutics, Inc.1 trial
- and 13 more
Running trials
Recruiting
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Personalized Therapy Study - Attain Stability Quad Post-Approval Study
Active, not recruiting
Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System
Active, not recruiting
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Acute myeloid leukaemia1 recruiting
- Liver and biliary tract cancer1 recruiting
- Multiple myeloma1 recruiting
- Parkinson disease1 recruiting
Closed trials
Withdrawn
A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease
Terminated
Completed
Recruiting
Completed
Completed
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Completed
Completed
Site data: ClinicalTrials.govUpdated 17 Nov 2026